The team have been very professional and attempted to correct the failings of TIS management. This could have imploded 3 - 4 years ago without us knowing if the product actually work.
At least now we know......
I find it interesting that on the call the final comments were that the standard of care across the subject sites was probably higher than the norm in normal practice - our product worked, but not any better than the normal best practice standard care.....
- Forums
- ASX - By Stock
- DLM
- Ann: Conference Call Details - Phase 2 Clinical Trial Results
Ann: Conference Call Details - Phase 2 Clinical Trial Results, page-5
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online